Different physiological and behavioural effects of e-cigarette vapour and cigarette smoke in mice

European Neuropsychopharmacology

Volumn 25, Issue 10, 2015, Pages 1775-1786

  Ponzoni, L ^a,e   Moretti, M ^a,b   Sala, M ^a,b   Fasoli, F ^a,b   Mucchietto, V ^a,b,e   Lucini, V ^a   Cannazza, G ^c   Gallesi, G ^c   Castellana, C N ^d   Clementi, F ^a,b   Zoli, M ^c   Gotti, C ^a,b   Braida, D ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e Fondazione Fratelli Confalonieri   (Italy)

Author keywords

Cigarette smoke; Electronic cigarettes, mecamylamine precipitated withdrawal; Nicotine; Nicotinic receptors; Spontaneous withdrawal

Indexed keywords

CIGARETTE SMOKE; COTININE; MECAMYLAMINE; NICOTINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA4BETA2; NICOTINIC AGENT; NICOTINIC RECEPTOR BLOCKING AGENT; PASSIVE SMOKING;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; BODY WEIGHT; BRAIN LEVEL; BRAIN REGION; COMPARATIVE STUDY; CONTROLLED STUDY; COTININE BRAIN LEVEL; ELECTRONIC CIGARETTE; ELEVATED PLUS MAZE TEST; EMOTIONALITY; FOOD INTAKE; IMMUNOPRECIPITATION; LEARNING AND MEMORY TEST; MALE; MARBLE BURYING TEST; MECHANICAL VENTILATOR; MOTOR ACTIVITY; MOUSE; NEUROCHEMISTRY; NEUROPHYSIOLOGY; NICOTINE BRAIN LEVEL; NONHUMAN; PASSIVE SMOKING; PRIORITY JOURNAL; RODENT MODEL; SMOKING CESSATION; SPATIAL ANALYSIS; SPATIAL OBJECT RECOGNITION; TOBACCO DEPENDENCE; UPREGULATION; URINALYSIS; URINE COTININE LEVEL; URINE LEVEL; WEIGHT GAIN; WORKING MEMORY; ADVERSE EFFECTS; ANIMAL; ARTIFICIAL VENTILATION; BAGG ALBINO MOUSE; BRAIN; DISEASE MODEL; DRUG EFFECTS; EATING; EMOTION; METABOLISM; PATHOPHYSIOLOGY; PSYCHOLOGY; SHORT TERM MEMORY; SPATIAL MEMORY; TOBACCO USE DISORDER; WITHDRAWAL SYNDROME;

ANIMALS; BODY WEIGHT; BRAIN; COTININE; DISEASE MODELS, ANIMAL; EATING; ELECTRONIC CIGARETTES; EMOTIONS; MALE; MECAMYLAMINE; MEMORY, SHORT-TERM; MICE, INBRED BALB C; NICOTINE; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; RECEPTORS, NICOTINIC; RESPIRATION, ARTIFICIAL; SPATIAL MEMORY; SUBSTANCE WITHDRAWAL SYNDROME; TOBACCO SMOKE POLLUTION; TOBACCO USE DISORDER;

EID: 84943352685     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2015.06.010     Document Type: Article

References (50)

1. Albelda N., Joel D. Animal models of obsessive-compulsive disorder: exploring pharmacology and neural substrates. Neurosci. Biobehav. Rev. 2012, 36:47-63.
2. Albanes D., Jones D.Y., Micozzi M.S., Mattson M.E. Associations between smoking and body weight in the US population: analysis of NHANES II. Am. J. Public Health 1987, 77:439-444.
3. Benowitz N.L., Dains K.M., Dempsey D., Herrera B., Yu L., Jacob P. Urine nicotine metabolite concentrations in relation to plasma cotinine during low-level nicotine exposure. Nicotine Tob. Res. 2009, 11:954-960.
4. Bevins RA, Besheer J Object recognition in rats and mice: a one-trial non-matching-to-sample learning task to study 'recognition memory. Nat. Protoc. 2006, 1:1306-1311.
5. Braida D., Limonta V., Malabarba L., Zani A., Sala M. 5-HT1A receptors are involved in the anxiolytic effect of Delta9-tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague-Dawley rats. Eur. J. Pharmacol. 2007, 555:156-163.
6. Brennan K.A., Laugesen M., Truman P. Whole tobacco smoke extracts to model tobacco dependence in animals. Neurosci. Biobehav. Rev. 2014, 47C:53-69.
7. Bullen C., Howe C., Laugesen M., McRobbie H., Parag V., Williman J., Walker N. Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet 2013, 382:1629-1637.
8. Bruijnzeel A.W. Tobacco addiction and the dysregulation of brain stress systems. Neurosci. Biobehav. Rev. 2012, 36:1418-1441.
9. Camfield D.A., Scholey A.B., Pipingas A., Silberstein R.B., Kure C., Zangara A, et al. The neurocognitive effects of Hypericum perforatum Special Extract (Ze 117) during smoking cessation. Phytother. Res. 2013, 27:1605-1613.
10. Castanê A., Valjent E., Ledent C., Parmentier M., Maldonado R., Valverde O. Lack of CB1 cannabinoid receptors modifies nicotine behavioral responses, but not nicotine abstinence. Neuropharmacology 2002, 43:857-867.
11. Catanzaro D.F., Zhou Y., Chen R., Yu F., Catanzaro S.E., De Lorenzo M.S., et al. Potentially reduced exposure cigarettes accelerate atherosclerosis: evidence for the role of nicotine. Cardiovasc. Toxicol. 2007, 7:192-201.
12. Chiolero A., Faeh D., Paccaud F., Cornuz J. Consequences of smoking for body weight, body fat distribution, and insulin resistance. Am. J. Clin. Nutr. 2008, 87:801-809.
13. Colombo S.F., Mazzo F., Pistillo F., Gotti C. Biogenesis, trafficking and up-regulation of nicotinic ACh receptors. Biochem. Pharmacol. 2013, 86:1063-1073.
14. Dawkins L., Turner J., Crowe E. Nicotine derived from the electronic cigarette improves time-based prospective memory in abstinent smokers. Psychopharmacology (Berl) 2013, 227:377-384.
15. Dawkins L., Turner J., Hasna S., Soar K. The electronic-cigarette: effects on desire to smoke, withdrawal symptoms and cognition. Addict. Behav. 2012, 37:970-973.
16. Domier C.P., Monterosso J.R., Brody A.L., Simon S.L., Mendrek A., Olmstead R., et al. Effects of cigarette smoking and abstinence on Stroop task performance. Psychopharmacology (Berl) 2007, 195:1-9.
17. George O., Grieder T.E., Cole M., Koob G.F. Exposure to chronic intermittent nicotine vapor induces nicotine dependence. Pharmacol. Biochem. Behav. 2010, 96:104-107.
18. Gotti C., Clementi F., Fornari A., Gaimarri A., Guiducci S., Manfredi I., et al. Structural and functional diversity of native brain neuronal nicotinic receptors. Biochem. Pharmacol. 2009, 78:703-711.
19. Gould T.J., Leach P.T. Cellular, molecular, and genetic substrates underlying the impact of nicotine on learning. Neurobiol. Learn. Mem. 2014, 107:108-132.
20. Grabus S.D., Martin B.R., Brown S.E., Damaj M.I. Nicotine place preference in the mouse: influences of prior handling, dose and strain and attenuation by nicotinic receptor antagonists. Psychopharmacology (Berl) 2006, 184:456-463.
21. Grady S.R., Moretti M., Zoli M., Mark M.J., Zanardi A., Pucci L., et al. Rodent habenulo-interpeduncular pathway expresses a large variety of uncommon nAChR subtypes, but only the alpha3beta4* and alpha3beta3beta4* subtypes mediate acetylcholine release. J. Neurosci. 2009, 29:2272-2282.
22. Hogg S A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacol. Biochem. Behav. 1996, 54:21-30.
23. Hughes J.R. Measurement of the effects of abstinence from tobacco: a qualitative review. Psychol. Addict. Behav. 2007, 21:127-137.
24. Hussmann G.P., Dedominicis K.E., Turner J.R., Yasuda R.P., Klehm J., Forcelli P.A., et al. Chronic sazetidine-A maintains anxiolytic effects and slower weight gain following chronic nicotine without maintaining increased density of nicotinic receptors in rodent brain. J. Neurochem. 2014, 10.1111/jnc.12653.
25. Kenney J.W., Adoff M.D., Wilkinson D.S., Gould T.J. The effects of acute, chronic, and withdrawal from chronic nicotine on novel and spatial object recognition in male C57BL/6J mice. Psychopharmacology (Berl) 2011, 217:353-365.
26. Kenny P.J., Markou A. Neurobiology of the nicotine withdrawal syndrome. Pharmacol. Biochem. Behav. 2001, 70:531-549.
27. Jung S., Lee I.S., Kim S.B., Moon C.S., Jung J.Y., Kang Y.A., Park M.S., Kim Y.S., Kim S.K., Chang J., Kim E.Y. Urine cotinine for assessing tobacco smoke exposure in Korean: analysis of the Korea national health and nutrition examination survey (KNHANES). Tuberc. Respir. Dis. 2012, 73:210-218.
28. Le Foll B., Goldberg S.R. Effects of nicotine in experimental animals and humans: an update on addictive properties. Handb. Exp. Pharmacol. 2009, 192:335-367.
29. Marks M.J., McClure-Begley T.D., Whiteaker P., Salminen O., Brown R.W., Cooper J., Collins A.C., Lindstrom J.M. Increased nicotinic acetylcholine receptor protein underlies chronic nicotine-induced up-regulation of nicotinic agonist binding sites in mouse brain. J. Pharmacol. Exp. Ther. 2011, 337:187-200.
30. Marks M.J., Pauly J.R., Gross S.D., Deneris E.S., Hermans-Borgmeyer I., Heinemann S.F., Collins A.C. Nicotine binding and nicotinic receptor subunit RNA after chronic nicotine treatment. J. Neurosci. 1992, 12:2765-2784.
31. Matta S.G., Balfour D.J., Benowitz N.L., Boyd R.T., Buccafusco J.J., et al. Guidelines on nicotine dose selection for in vivo research. Psychopharmacology (Berl) 2007, 190:269-319.
32. Mineur Y.S., Abizaid A., Rao Y., Salas R., DiLeone R.J., Gündisch D., et al. Nicotine decreases food intake through activation of POMC neurons. Science 2011, 332:1330-1332.
33. Moretti M., Mugnaini M., Tessari M., Zoli M., Gaimarri A., et al. A comparative study of the effects of the intravenous self-administration or subcutaneous minipump infusion of nicotine on the expression of brain neuronal nicotinic receptor subtypes. Mol. Pharmacol. 2010, 78:287-296.
34. Nguyen H.N., Rasmussen B.A., Perry D.C. Binding and functional activity of nicotinic cholinergic receptors in selected rat brain regions are increased following long-term but not short-term nicotine treatment. J. Neurochem. 2004, 90:40-49.
35. Paolini M., De Biasi M. Mechanistic insights into nicotine withdrawal. Biochem. Pharmacol. 2011, 82:996-1007.
36. Piasecki T.M., Baker T.B. Any further progress in smoking cessation treatment?. Nicotine Tob. Res 2001, 3:311-323.
37. Picciotto M.R. Nicotine as a modulator of behavior: beyond the inverted U. Trends Pharmacol. Sci. 2003, 24:493-499.
38. Pistelli F., Aquilini F., Carrozzi L. Weight gain after smoking cessation. Monaldi Arch. Chest Dis. 2009, 71:81-87.
39. Pistillo F., Clementi F., Zoli M., Gotti C. Nicotinic, glutamatergic and dopaminergic synaptic transmission and plasticity in the mesocorticolimbic system: focus on nicotine effects. Prog. Neurobiol. 2015, 124:1-27.
40. Rodgman A, Smith C.J., Perfetti T.A. The composition of cigarette smoke: a retrospective, with emphasis on polycyclic components. Hum. Exp. Toxicol. 2000, 19:573-595.
41. Rose J.E. Nicotine and non nicotine factors in cigarette addiction. Psychopharmacology (Berl) 2006, 184:274-285.
42. Sala M., Braida D., Donzelli A., Martucci R., Busnelli M., Bulgheroni E., et al. Mice heterozygous for the oxytocin receptor gene (Oxtr(+/-) show impaired social behavior but not increased aggression or cognitive inflexibility: evidence of a selective haploinsufficiency gene effect. J. Neuroendocrinol. 2013, 25:107-118.
43. Stoker A.K., Semenova S., Markou A. Affective and somatic aspects of spontaneous and precipitated nicotine withdrawal in C57BL/6J and BALB/cByJ mice. Neuropharmacology 2008, 54:1223-1232.
44. Thomas A, Burant A., Bui N., Graham D., Yuva-Paylor L.A., Paylor R. Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety. Psychopharmacology (Berl) 2009, 204:361-373.
45. Turner J.R, Castellano L.M., Blendy J.A. Nicotinic partial agonists varenicline and sazetidine-a have differential effects on affective behaviour. J. Pharmacol. Exp. Ther. 2010, 334:665-672.
46. Varani A.P., Moutinho L.M., Bettler B., Balerio G.N. Acute behavioural responses to nicotine and nicotine withdrawal syndrome are modified in GABA(B1) knockout mice. Neuropharmacology 2012, 63:863-872.
47. Vieira-Brock PL, Miller EI, Nielsen SM, Fleckenstein AE, Wilkins DG Simultaneous quantification of nicotine and metabolites in rat brain by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2011, 879:3465-3474.
48. Wing V.C., Sacco K.A., George T.P. Spatial working memory impairments induced by cigarette smoking abstinence are correlated with plasma nicotine levels in schizophrenia. Schizophr. Res. 2011, 128:171-172.
49. World Health Organization (WHO). Marketers of electronic cigarettes should halt unproved therapy claims.19 September 2008. Available online: ). http://www.who.int/mediacentre/news/releases/2008/pr34/en/.
50. Yohn N.L., Turner J.R., Blendy J.A. Activation of α4β2*/α6β2* Nicotinic receptors alleviates anxiety during nicotine withdrawal without upregulating nicotinic receptors. J. Pharmacol. Exp. Ther. 2014, 349:348-354.